logo-loader
viewMerck & Co., Inc.

The Edge CEO: Why Merck & Co should spin off its animal health division

The Edge Consulting Group CEO Jim Osman tells Proactive Investors the investment research company that focuses on company spin-offs has compiled a report suggesting Merck & Co (NYSE:MRK) spin-off its animal health business, as the animal health business generates around $40 billion in revenue, The Edge expecting this to rise to $65 billion in 2025.

Osman says there's significant value to be held to create even more value for its investors if the pharma giant does indeed spin off this portion of the business.

Quick facts: Merck & Co., Inc.

Price: 90.97 USD

NYSE:MRK
Market: NYSE
Market Cap: $231.61 billion
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Bulls, Bears & Brokers: Alto Capital’s Tony Locantro on Nyrada IPO and small...

Alto Capital investment manager and stock market commentator Tony Locantro updates Proactive on this week's listing of Nyrada Inc (ASX:NYR), a spin-off of Noxopharm Ltd’s (ASX:NOX). He discusses the reasons for the spin-off, including some of the recent and expected trading patterns. Locantro...

2 days ago

2 min read